{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056284","form_type":"8-K","ticker":"LNSR","cik":"0001320350","company_name":"LENSAR, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.825612+00:00","generated_at":"2026-06-02T05:06:12.882856+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"LENSAR Q1 revenue $10.6M (+28% YoY); net loss narrows to $2.2M","bullets":["Total revenue $10.6M for Q1 2024, up 28% YoY; net loss $2.2M ($0.19 per share) vs $4.3M ($0.40) loss in Q1 2023.","Worldwide procedure volume increased 25% to 39,486; U.S. procedure volume up 23%. Installed base of ALLY systems reached 65.","U.S. procedure share grew 1.5% sequentially from Q4 2023, the highest single-quarter gain since ALLY launch; total share up 4.3% since launch.","Adjusted EBITDA loss improved to $1.3M from $1.8M; SG&A flat at $6.8M, R&D down 12% to $1.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056284","json":"https://secwatch.observer/filing/0000950170-24-056284.json","markdown":"https://secwatch.observer/filing/0000950170-24-056284.md","text":"https://secwatch.observer/filing/0000950170-24-056284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1320350/000095017024056284/0000950170-24-056284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1320350/000095017024056284/lnsr-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:06:12.882856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09668ed126dd1f39d603789fa292e2f50b5ca733","claim":"LENSAR, Inc. reported quarter ended March 31, 2024 results: revenue $10.6 million, net income $2.2 million, EPS ($0.19) per common share.","evidence_excerpt":"and staff as well as better surgical outcomes for patients, allowed us to deliver continued 20%+ revenue growth in the first quarter of 2024. Total revenue for the quarter was $10.6 million, up 28% over the first quarter of 2023. Moreover, procedure volume grew by 23% in the U.S., our largest market and the only country where ALLY is currently marketed,” said Nick","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1320350/000095017024056284/0000950170-24-056284-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$10.6 million"},{"label":"Net income","value":"$2.2 million"},{"label":"EPS","value":"($0.19) per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}